Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 36Completed 12Not yet recruiting 11Active not recruiting 8Terminated 2Withdrawn 1Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gallbladder Neoplasms 1Disease Progression 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

pembrolizumab 116Carboplatin 48Nivolumab 46Paclitaxel 35Cyclophosphamide 35Cisplatin 34Gemcitabine 30atezolizumab 25Specimen Handling 25venetoclax 24Pemetrexed 24Magnetic Resonance Spectroscopy 24fludarabine 22Ipilimumab 22Docetaxel 22Bevacizumab 22Biopsy 21Radiotherapy 20Azacitidine 20Fluorouracil 19Dexamethasone 19Radiosurgery 18durvalumab 17Leucovorin 16olaparib 14Trastuzumab 14Cetuximab 14Capecitabine 14fludarabine phosphate 13Lenalidomide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Folfox protocol × 1 year × Clear all
NCT05712356 2026-05-26

BOLSTER

Lisata Therapeutics, Inc.

Phase 2 Terminated
66 enrolled 12 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT05171166 2025-12-18

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Peking University

Phase 2/3 Terminated
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡